✦ LIBER ✦

Agalsidase-β achieves long term efficacy in Fabry's disease

Book ID: 120847207
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 151 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200715930-00023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Agalsidase-Β appears effective in Fabry'

Agalsidase-Β appears effective in Fabry's disease

📂 Article 📅 2004 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Early agalsidase-β beneficial in Fabry's

Early agalsidase-β beneficial in Fabry's disease

📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Enzyme replacement therapy with agalsida

Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease

✍ L Spinelli; A Pisani; M Sabbatini; M Petretta; MV Andreucci; D Procaccini; N Lo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Promising long-term results for α-galact

Promising long-term results for α-galactosidase in Fabry's disease

📂 Article 📅 2001 🏛 Adis International Limited (now part of Wolters Kl ⚖ 133 KB

Long-term agalsidase beta therapy is ass

Long-term agalsidase beta therapy is associated with improvements in pain and quality of life among patients with Fabry disease

✍ N. Guffon; D.P. Germain; S. Waldek; M. Banikazemi; D.A. Bushinsky; J. Charrow; P 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Long-term antidyskinetic efficacy of ama

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

✍ Elisabeth Wolf; Klaus Seppi; Regina Katzenschlager; Guenter Hochschorner; Gerhar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodop